Company intelligence / Profile preview

Hologen AI

Ownership: Private
Development stage: Phase 3

Overview

Hologen AI has committed up to $430 million to help advance MeiraGTx's Parkinson's disease gene therapy (AAV-GAD) through Phase 3 trials and to commercialization. Their AI technology has already been used to identify disease-modifying changes in brain physiology in Phase 2 trial patients[1][3].

Therapeutic areas: EndocrinologyNeurology
Modalities: Gene therapy
Industry: Drug Discovery Services

Drug pipeline

2 assets

AAV-GAD

Phase 3

Indications: Parkinson's disease

1 more asset in the full pipeline.

Request access →

Partnerships

MeiraGTx Holdings (strategic collaboration with $430M commitment and joint venture)[1][2]

Beyond the preview

Go deeper on Hologen AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hologen AI.

Explore the full profile